Chronos Therapeutics

About Chronos Therapeutics

Chronos Therapeutics Limited is a UK-based biotechnology company focused on developing treatments for central nervous system (CNS) disorders, specifically targeting degenerative and behavioral brain diseases. Founded in 2009 and headquartered in Oxford, the company operates on a semi-virtual research and development model. Its strategy involves both the development of novel proprietary drug candidates and the repositioning of existing, approved drugs for new therapeutic applications in areas with significant unmet medical needs.

In April 2024, Chronos Therapeutics was acquired by TheraCryf plc (formerly Evgen Pharma plc) for up to £3.4 million. This acquisition integrated Chronos as a wholly-owned subsidiary of TheraCryf, expanding the latter's R&D portfolio. The deal added Chronos's late preclinical-stage assets to TheraCryf's pipeline, including an orexin-1 (Ox-1) antagonist for impulsivity, anxiety, and addiction disorders, and an atypical dopamine transporter (DAT) inhibitor for fatigue and the orphan condition narcolepsy. This strategic move was designed to leverage Chronos's specialization in neuropsychiatry alongside TheraCryf's focus on oncology and neurodevelopmental disorders.

Chronos has a history of collaboration within the pharmaceutical industry. A notable partnership involved acquiring three preclinical development programs from a subsidiary of Shire, which also became an equity investor in Chronos. The company's business model is centered on advancing its programs to generate compelling proof-of-concept data, with the ultimate goal of partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. The leadership team included CEO Dr. Huw Jones, who has over 30 years of experience in the biotechnology and pharmaceutical sectors and became CEO of the parent company, TheraCryf, following the acquisition.